Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cutaquig Modified Dosing in Primary Immunodeficiency
NCT03939533Phase 3Completed
- Sponsor
- Octapharma
- Start
- Oct 2019
- Primary completion
- Jan 2022
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, open-label trial of polyvalent human immunoglobulin in primary immunodeficiency disease (PID) (3 arms), sponsored by Octapharma. Primary endpoint: IgG Trough Levels From Baseline to End of Study at 28 weeks. Started Oct 2019; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT03939533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939533.